Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported new analysis of data from the Company's pivotal PROPEL trial of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The objective of this retrospective subgroup analysis was to assess the activity and safety of single-agent FOLOTYN in patients enrolled in PROPEL who were diagnosed with histologically confirmed relapsed or refractory transformed mycosis fungoides (tMF), which is an aggressive and difficult to treat T-cell lymphoma.
New “Call To Action” Sets Road Map For Future Research and Treatment. Get more information or view/download the entire Proceedings document published in the Journal of Clinical Lymphoma, Myeloma & Leukemia.
The editors of the prestigious Journal of Investigative Dermatology have recognized the Cutaneous Lymphoma Foundation, and its contribution to patient advocacy, in the July, 2010 edition of the Journal.
With over 15 years of nonprofit management, fund development, communications, marketing and public relations experience, Jennifer A. Viano joined the Cutaneous Lymphoma Foundation in April 2010 as its new Chief Executive Officer.